Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532910 | 0.82 | P2RX7 (0.49) | CYP2C9NAMPTP2RX7GABRA5 | |
| SCHEMBL17886855 | 0.80 | CYP2C9 (0.42) | CYP2C9NAMPTP2RX7GABRA5 | |
| SCHEMBL17888348 | 0.80 | GAA (0.42) | CYP2C9NAMPTP2RX7SLC6A4SLC6A2 | |
| SCHEMBL8550272 | 0.79 | ADRA2C (0.46) | CYP2C9NAMPTP2RX7GABRA5HTR2A | |
| SCHEMBL16619259 | 0.78 | MCL1 (0.44) | CYP2A6SLC6A4SLC6A2SLC6A3MCL1 | |
| SCHEMBL7416949 | 0.78 | KDM1A (0.49) | CYP2A6SLC6A4SLC6A2SLC6A3MCL1 | |
| SCHEMBL7937049 | 0.78 | CYP2A6 (0.41) | CYP2A6SLC6A4SLC6A2SLC6A3MCL1 | |
| SCHEMBL5768182 | 0.78 | KDM1A (0.49) | P2RX7CYP2A6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7925387 | 0.78 | CYP2A6 (0.41) | CYP2C9CYP2A6SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31509923 | 0.78 | CYP2A6 (0.41) | CYP2A6SLC6A4SLC6A2SLC6A3MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021003398-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-01-07 | — | — | WO | disclosed |
| EP-3038466-B1 | 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2978764-B1 | PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) | SANOFI SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160060265-A1 | PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CYP2C9 321/4885NAMPT 1885/4885P2RX7 247/4885 |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | CYP2C9 934/4885NAMPT 2537/4885P2RX7 24/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CYP2C9 3111/4885NAMPT 2312/4885P2RX7 89/4885 |
| US-20160060265-A1 | PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) | METAP2, METAP1, XPNPEP2 | CYP2C9 742/4885NAMPT 545/4885P2RX7 1258/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CYP2C9 321/4885NAMPT 1885/4885P2RX7 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.